HALIFAX, NS / ACCESS Newswire / January 21, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its recently Health Canada approved Multiplo® TP/HIV rapid test. These applications include use as a self-test and for non-professional administration, expanding access to testing... Read More

HALIFAX, NS / ACCESSWIRE / January 14, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal® HIV test) for Point-of-Care (POC) use. The Reveal® HIV rapid test has achieved a sensitivity of 99.64% and a specificity of 99.71% and with it is highly suitable for health care professionals who require a fast, reliable, and... Read More

HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials for its Multiplo ® Complete Syphilis (TP/nTP) Antibody Test (Multiplo ® TP/nTP), a cutting edge device that can determine active and non-active syphilis. The upcoming trials will be led by REACH Nexus at the MAP Centre for... Read More

HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025, MedMira has been continuing its regulatory work and clinical trials for its Reveal® G4 HIV-1/2 rapid test CLIA-waiver and with it made substantial progress on its FDA application. At the same time, the Company achieved a number of... Read More

HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo ® Rapid TP/HIV Test (Multiplo ® TP/HIV) to be rolled out across Canada, a critical point-of-care tool to address the health crises with HIV and syphilis in Canada. The single Reveal® TP (Syphilis) approval will follow soon after... Read More

HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December 2023, the Company received the 510(k) (FDA) approval for its Reveal® G4 Rapid HIV-1/2 antibody test. The Company's completed clinical trials showed a sensitivity of 100% for HIV-1 and HIV-2 MedMira's Reveal® G4 HIV-1/2 rapid antibody... Read More

MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as Vice President of Commercial Operations, effective immediately. Ms. Crenshaw's addition strengthens MedMira's leadership team as the company targets significant growth across its commercial portfolio. Ms. Crenshaw brings over 25... Read More

HALIFAX, NS / ACCESSWIRE / August 13, 2024 / Today, MedMira Inc . (MedMira) (TSXV:MIR) announces it will conduct full clinical trials for its unique Multiplo ® Complete Syphilis (TP/nTP) Antibody Test (Multiplo ® TP/nTP) with the goal of getting it licensed in Canada. The new Multiplo ® TP/nTP will provide a complete system which combines screening and confirmation in one test. Just announced by Health Minister Mark Holland... Read More

HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024. Corporate update In Q3 FY2024, MedMira focused on the launch of MedMira's latest US FDA approved Reveal ® G4 Rapid HIV 1/2 antibody test and continued its regulatory work in Canada and the United States. At the same time, the Company collaborated with a third party to... Read More

HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of Vice President of Business Development. Ms. Bell brings over 20 years of Business Development and Sales experience in the United States and international markets. Her extensive knowledge of the US healthcare market, coupled with... Read More

HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024. Corporate update During Q2 FY2024, MedMira received the US FDA 510(k) clearance for the HIV-2 claim on the Reveal ® G4 Rapid HIV-1/2 antibody test in the United States. This major milestone allows the Company to significantly grow its market share and revenue in the... Read More

HALIFAX, NS / ACCESSWIRE / March 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of a Canadian patent patent (number 2,949,634) for its new innovative and quantitative test system. This is in addition to the U.S. patent (number 11,353,450) received in 2022. Through this new patent, MedMira is to further diversify its patent portfolio and expand on its Rapid Vertical Flow Technology ® (RVF) based... Read More

Correction: Extended clarification. HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the submission and since then has been working with the regulator on the additional clarifications and at the same time has been working towards extending its intended use highlighting the increasing need in... Read More

HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the required submission and has been working towards extending its intended use highlighting the increasing need in maternity screening. MedMira is committed to provide the fastest and most accurate solution to the increasing infection rates... Read More

HALIFAX, NS / ACCESSWIRE / December 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2023. Corporate update During Q1 FY2024, MedMira continued its focus on its regulatory and clinical trial work for a number of products, while increasing its sales and marketing activities. Throughout the reporting period, the Company achieved significant milestones in... Read More

HALIFAX, NOVA SCOTIA / ACCESSWIRE / December 13, 2023 / MedMira Inc. (MedMira) (TSXV:MIR) proudly announces today the successful attainment of 510(k) clearance for the HIV-2 claim on the Reveal ® G4 Rapid HIV-1/2 antibody test in the United States. This achievement marks a significant milestone for MedMira, positioning the company as a key player in the HIV testing landscape and addressing the demand for comprehensive HIV... Read More

HALIFAX, NS / ACCESSWIRE / November 28, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2023. Corporate Update Throughout the reporting period, the Company achieved significant milestones in its pursuit of FDA and Health Canada approvals for a range of products. A standout accomplishment is the progress made with MedMira's 510(k) (FDA) approval for its... Read More

HALIFAX, NS / ACCESSWIRE / September 27, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) provides an update on its progress to achieve regulatory approval in Canada and the USA for its infectious disease rapid tests. Currently the Company has two submissions filed with Health Canada and one submission with the US FDA. In addition, the Company is in the process to complete its clinical trials and subsequently gather all... Read More

HALIFAX, NS / ACCESSWIRE / August 30, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) has completed, with its Transfer Agent, the process and has received confirmation by the TSX.v as follows: "Further to the resumption of trading of the shares of MedMira Inc., (the "Company"), the Exchange advises that effective at the opening, Friday, September 1, 2023, the shares of the Company will resume trading. The Exchange Bulletin... Read More

HALIFAX, NS / ACCESSWIRE / June 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2023. Corporate Update Summary During the third financial quarter of 2023, MedMira continued its focus on its regulatory and clinical trial work for five products related to Sexually Transmitted Infections (STI) and Respiratory Viruses. In March 2023, the Company started its... Read More

HALIFAX, NS / ACCESSWIRE / April 3, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2023. Corporate Update Summary During the second financial quarter of 2023, MedMira continued its focus on its COVID-19 and Sexually Transmitted Infections (STI) product lines while continuing its work for its unique patented quantitative diagnostic system - MiRO Q.... Read More

HALIFAX, NS / ACCESSWIRE / March 14, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) provides an update on its progress to achieve regulatory approval in Canada for its Reveal ® TP (Syphilis) antibody test. The Company has successfully started its clinical trials in Saskatchewan in early March 2023 and commences its the other trial in British Colombia by the end of this month. MedMira's Reveal ® TP (Syphilis) antibody rapid... Read More

HALIFAX, NS / ACCESSWIRE / February 20, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the singing of a multinational distribution agreement with ​ Maternova, Inc. , Rhode Island, USA. ​Maternova is a US-based distribution company specialising in maternal and infant health through innovative, accessible solutions.Under the agreement, Maternova will have exclusive distribution rights across Latin America and... Read More

PROVIDENCE, R.I. & HALIFAX, Nova Scotia / Feb 20, 2023 / Business Wire / Maternova, Inc. , accelerating advances in maternal and infant health through innovative, accessible solutions, and MedMira Inc. (TSXV: MIR), a developer and manufacturer of rapid diagnostics, today announced that the companies have entered into a multinational distribution agreement. Under the agreement, Maternova will have exclusive distribution... Read More

HALIFAX, NS / ACCESSWIRE / January 11, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of the CE mark for its VYRA™ CoV2Flu Antigen Test (VYRA™ CoV2Flu), the fastest combination antigen test available to detect SARS-CoV-2, Flu A and Flu B. The Company received the CE mark and VYRA™ CoV2Flu is now... Read More

HALIFAX, NS / ACCESSWIRE / January 3, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection - ( available: https://www.mdpi.com/2076-0817/12/1/77 ), in the special edition of Pathogens by MDPI, a Swiss based medical journal. The article written by Professor John Alderete from the School of... Read More

HALIFAX, NS / ACCESSWIRE / December 30, 2022 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2022. Corporate Update Summary During the first financial quarter of 2023, MedMira continued its focus on its COVID-19 and Sexually Transmitted Infections (STI) product lines while continuing its work for its unique quantitative diagnostic system - MiRO Q . This proven... Read More

HALIFAX, NS / ACCESSWIRE / December 29, 2022 / Today, MedMira Inc. (MedMira) (TSXV:MIR) presents its latest addition to the VYRA TM product line, the VYRA TM TriDemic Antigen Rapid Test for the simultaneous detection of SARS-CoV-2, Flu A, Flu B and Respiratory Syncytial Virus (RSV). VYRA TriDemic, a four-in-one test, which is... Read More

HALIFAX, NS / ACCESSWIRE / November 29, 2022 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2022. Profit and Loss Highlights Revenue: The Company recorded sales and service revenues in FY2022 of $952,127 compared to $2,144,470 in FY2021. The decrease was mainly due to a temporary halt in sales for its COVID-19 product line which has been a major contributor... Read More